Apotex Pty Ltd v Les Laboratoires Servier (No 2)

Link copied
Case Copied 60 min read

FEDERAL COURT OF AUSTRALIA

Apotex Pty Ltd v Les Laboratoires Servier (No 2) [2012] FCA 748

Citation: Apotex Pty Ltd v Les Laboratoires Servier (No 2)
[2012] FCA 748
Parties: APOTEX PTY LTD ACN 096 916 148 v LES LABORATOIRES SERVIER; LES LABORATOIRES SERVIER and SERVIER LABORATORIES (AUST) PTY LTD ACN 004 838 500; APOTEX PTY LTD and SYMBION PTY LTD ACN 000 875 034
File number: NSD 51 of 2012
Judge: BENNETT J
Date of judgment: 13 July 2012
Catchwords:

PRACTICE & PROCEDURE – Service outside Australia – whether overseas entities that were part of the same corporate group should be joined to proceeding – whether Court has a discretion to make or refuse an order granting leave to serve a party outside Australia under Rule 10.43 Federal Court Rules 2011

PATENTS – prima facie case – authorisation of infringement – joint tortfeasorship by common design

PRACTICE & PROCEDURE – Quia timet relief – whether available in circumstances where there is an interim injunction by consent – no primary infringement and no threat of a primary infringement

Legislation: Copyright Act 1968 (Cth) s 101(1A)
Federal Court Rules 2011, Division 1.2, 1.3 and 10.4, Rules 10.42 and 10.43
Federal Court of Australia Act 1976 (Cth) s 37M
Patents Act 1990 (Cth) s 13 and Schedule 1
Therapeutic Goods Act 1989 (Cth) s 3(1)
Cases cited: Alcoa of Australia Ltd (ACN 004 879 298) v Australian Workers’ Union (2010) 196 IR 103 followed
Apotex Pty Ltd v Les Laboratoires Servier (No 4) (2010) 89 IPR 274 distinguished
Australasian Performing Right Association Ltd v Metro on George (2004) 210 ALR 244 cited
Bell v Steele (2011) 198 FCR 291
Bray v F Hoffman-La Roche (2002) 118 FCR 1 cited
CSL Ltd v Glaxosmithkline (2006) 70 IPR 128 cited
Century Insurance(in provisional liquidation) v New Zealand Guardian Trust [1996] FCA 376 cited
Ho v Akai Pty Ltd (in liq) (2006) 24 ACLC 1526 followed
Humane Society International Inc v Kyodo Senpaku Kaisha Ltd (2006) 154 FCR 425 cited
Inverness Medical Switzerland GMBH v MPS Diagnostics Pty Ltd (2010) 85 IPR 525 cited
Magic Menu Systems Pty Ltd v AFA Facilitation Pty Ltd (1997) 72 FCR 261 cited
MeadCorporation v Riverwood Multiple Packaging [1997] FSR 484 cited
Morton-Norwich Products Inc v Intercen Limited [1978] RPC 501 followed
Nationwide News Pty Ltd v Copyright Agency Ltd (1996) 65 FCR 399 cited
Perdaman Chemicals and Fertilisers v Griffin Coal Mining Co Pty Ltd [2011] FCA 1425 cited
RCA Corporation v John Fairfax Sons [1981] 1 NSWLR 251 cited
Roadshow Films Pty Ltd v iiNetPty Ltd (2012) 286 ALR 466 discussed
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (2010) 88 IPR 459 cited
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (2010) 88 IPR 633 cited
Suzlon Energy Ltd v Bangad (No 3) [2012] FCA 123 cited
Unilever PLC v ChefaroProprietaries Ltd [1994] FSR 15 discussed
Unilever PLC v Gillette (UK) Ltd [1989] distinguished
WEA International v Hanimex Corp Ltd (1987) 17 FCR 274
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Apotex Pty Ltd v Les Laboratoires Servier (No 2) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2012] FCA 748
Decision Date

CaseChat Overview and Summary

Apotex Pty Ltd v Les Laboratoires Servier (No 2) involved a dispute between Servier and Apotex regarding the validity and infringement of a patent. The case was heard in the Federal Court of Australia. The central issue was whether Servier could obtain a quia timet injunction against overseas entities, which were part of the Apotex group, based on a prima facie case of authorisation of infringement or a common design to infringe the patent.

The court examined whether there was sufficient evidence to support a prima facie case of infringement by the overseas entities. Servier argued that each of the overseas entities manufactured and supplied pharmaceutical products for sale in Australia, and that Apotex Inc also imported such products. The court considered the corporate structure of the Apotex group and whether the overseas entities were sufficiently connected to Apotex Pty Ltd to be considered part of a common design or authorisation to infringe the patent. The court found that there was insufficient evidence to support the inference that the overseas entities were involved in a common design or authorisation to infringe the patent.

The court concluded that there was no present infringement of the patent and no present threat of an infringement. The court held that there was no basis for a quia timet injunction because there was no actual or apprehended infringement and no other party to the joint tortfeasance by common design or an infringement, actual or apprehended to be authorised. The court further held that an injunction must be of some practical utility and the court should not enjoin conduct that in all probability will not occur.

The court's decision was based on the specific circumstances of the case, including the fact that Apotex Pty Ltd had proffered consent to an injunction and had admitted that the product in question was within the scope of the patent claims. The court held that if the patent was determined to be invalid, there could be no infringement, and if the patent was valid, Apotex Pty Ltd would be subject to a permanent injunction restraining exploitation of the product. The court also noted that there was no evidence that Apotex Pty Ltd would sell or attempt to sell the product if the patent were held to be valid or pending the determination of the validity of the patent.

The court's decision highlights the importance of establishing a prima facie case of infringement and the need for sufficient evidence to support a claim of joint tortfeasance by common design or authorisation. The decision also emphasises the need for an injunction to be of some practical utility and not to enjoin conduct that in all probability will not occur. The case serves as a reminder that the grant of an injunction is not automatic and requires careful consideration of the specific circumstances of each case.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Although I have found that, in the circumstances of the current injunction, Servier is generally unable to obtain a quia timet injunction, I will nonetheless consider the evidence advanced by Servier in support of a prima facie case of authorisation of infringement or of a common design to infringe the Patent by each overseas cross-respondent. The evidence in support of a prima facie case against each of the overseas cross-respondents Servier pleads that each of the overseas cross-respondents manufactures and supplies pharmaceutical products for sale and use in Australia, and that Apotex Inc also imports pharmaceutical products for sale and use in Australia. The Apotex corporate group Servier states that Apotex is a vertically integrated corporate group or a single worldwide organisation, relying on extracts from the Apotex Worldwide website. The organisational structure, by reason of shareholding, is not in dispute. Both parties accept the corporate structure that reflects the shareholding is as follows: XXXXX X XXXXX Servier relies on an affidavit sworn in March 2007 in Federal Court Proceeding NSD 208 of 2007 by Mr Millichamp, the managing director of what was then called GenRx Pty Ltd (GenRx) (now Apotex P/L). He said that GenRx was a wholly owned subsidiary of Apotex Australia Pty Ltd which was a wholly owned subsidiary of Apotex Inc. Servier contends that, despite the corporate structure, as a matter of reality Apotex P/L functions as a wholly owned subsidiary of Apotex Inc. Servier submits that this is sufficient to establish that fact at the level of a prima facie case. Apotex P/L says that the asserted fact is incorrect. It notified Servier of the mistake by letter in June 2010, asserting that Apotex P/L is not and never has been a subsidiary, direct or indirect, of Apotex Pharmachem or of Apotex Inc. With reference to the latter, the letter stated that it is not clear how this ‘error in our client’s understanding arose’. I accept Apotex P/L’s explanation that the Mr Millichamp was in error in his earlier affidavit and that the corporate structure is as depicted in the diagram. That is, there is no direct control of Apotex P/L by Apotex Pharmachem or Apotex Inc. I reject the inference sought to be drawn by Servier that, despite the explanation provided by Apotex in correspondence soon after the filing of the affidavit that it was a mistake in the accepted corporate structure; Apotex Inc was, in reality and practice somehow controlling Apotex P/L. The evidence does not support that fact or inference, even at a prima facie level.The TGA file Servier relies on the information from the TGA Drug Master File (DMF) submitted by Apotex P/L for the Apotex Product. The drug product sponsor is Apotex P/L. Information from the TGA website provides instructions as to the content of a DMF. The drug product sponsor must have the written permission of the drug substance manufacturer who submitted the DMF. The letter of access to the TGA must indicate, inter alia, the product sponsor and provide ‘certain other information and assurances required by the TGA’. An overseas manufacturer may submit all necessary documentation on behalf of multiple sponsors. It is the sponsor that is responsible for the quality of the product and the raw materials used to manufacture it. The sponsor provides written assurance that there is a formal agreement between the manufacturer of the API and the sponsor designed to ensure that information will be communicated by the manufacturer to the sponsor and the TGA before any significant change is made to the drug substance. The manufacturer provides the DMF and must complete the pro forma letter of access to it available from the TGA website. A separate application is required for each sponsor and each manufacturing site.

Decision

Reasons for decision

The only claim of direct infringement asserted against the overseas cross-respondents is that each “supplied” the Apotex Product to Apotex P/L in the Patent Area. This was not addressed by Servier in its submissions as a basis for the prima facie case against any of the overseas cross-respondents. I have therefore not addressed it in these reasons. In any event, I consider that Servier would have been unable to establish a prima facie case for direct infringement. As Apotex P/L points out:·There is no evidence of any supply by Apotex P/L or by any of the overseas cross-respondents of perindopril arginine in Australia. ·Neither Apotex Inc not Apotex Pharmachem can currently manufacture or supply any form of perindopril because of an injunction in Canada.·Apotex Pharmachem and XXXXX XXXXX XXX only manufacture APIs and not finished products. On that basis neither could be suppliers of finished perindopril arginine products to Apotex P/L in Australia. Conclusion There is no present infringement of the Patent and there is no present threat of an infringement of the Patent in circumstances where:·Apotex P/L has proffered consent to an injunction;·Apotex P/L has admitted that the Apotex Product is within the scope of the claims of the Patent;·there is no present issue of infringement;·the question for determination is the validity of the Patent;·if the Patent is determined to be invalid, there can be no infringement;·if the Patent is valid, Apotex P/L would be subject to a permanent injunction restraining exploitation of the Apotex Product;·the evidence relied upon by Servier is directed to the Apotex Product;·there is no evidence that Apotex P/L would sell or attempt to sell the Apotex Product if the Patent were held to be valid; and·there is no evidence that Apotex P/L will sell or attempt to sell the Apotex Product pending the determination of the validity of the Patent. There is no basis for a threatened infringement of the Patent by way of joint tortfeasorship for common design or authorisation of a product other than the Apotex Product or through a conduit other than Apotex P/L:·There is no sufficient evidence that any of the overseas cross-respondents has an intention to or has threatened to participate in another infringing act.·The only primary infringement that could be said to be threatened is of the sale in Australia of the Apotex Product by Apotex P/L and that threat is not current or reasonably apprehended.·There is no actual or apprehended primary infringement and there is no other party to the joint tortfeasance by common design or an infringement, actual or apprehended to be authorised.·There is no past infringement or previous unlawful action. Servier has not demonstrated a present intention on the part of the overseas cross-respondents to do an act not authorised by law (see Halsbury’s Laws of Australia at [185–1560] and Spry at 381). An injunction must be of some practical utility and the Court should not enjoin conduct that in all probability will not occur. There is no present basis sufficient for a quia timet injunction.

Ratio Decidendi

Legal Principle Established

Apotex P/L emphasises that:·because of the injunction restraining the sale, or other exploitation by it, of the Apotex Product, there is no tort being committed;·there is no question of damage presently arising or likely to arise;·infringement is not in issue;·if the Patent is valid, there will be no relevant exploitation by Apotex P/L in Australia; and·if the Patent is invalid, there will be no damage suffered by Servier if Apotex P/L then sells the Apotex Product. Consideration In Apotex (No 4), I considered whether parties could be joined to the proceeding if they were considered joint tortfeasors by common design and authorisation. In that case, the accumulation of evidence was held sufficient to support a case of common design and an order for joinder of the overseas company Apotex Pharmachem. This evidence included:·the existence of a vertically integrated group of companies, including Apotex P/L and Apotex Pharmachem;·manufacture of the active pharmaceutical ingredient (API) of the Australian product by Apotex Pharmachem;·the sale of the allegedly infringing product in Australia by Apotex P/L;·Apotex Pharmachem provided information and played an active role in obtaining approval for the Australian product under the Therapeutic Goods Act 1989 (Cth) (TG Act); and·Apotex Pharmachem manufactured the API in circumstances where it knew of the patent that was in dispute in that proceeding. There are differences between the present circumstances and those that existed in Apotex (No 4), including:·the allegedly infringing products were being sold in Australia and this conduct was not the subject of an interim injunction;·Apotex Pharmachem’s manufacture of the API and its role in obtaining and maintaining Therapeutic Goods Administration (TGA) approval was in that context; and·infringement was in issue and joinder was pressed in part to obtain information from Apotex Pharmachem, as the manufacturer of the API, said to be necessary for Servier’s case on infringement. Servier relies on the decision in Unilever PLC v Gillette (UK) Ltd [1989] RPC 583. In that case, the plaintiffs referred to a number of factors said to found an inference that an overseas parent company was involved in a common design with the local UK company. The factors were that the overseas parent company:1.wholly owned Gillette UK (through another subsidiary);2.sold the allegedly infringing product to Gillette UK;3.was aware of the patent at the time of sale;4.was party to a know-how agreement with Gillette UK;5.exercised a worldwide right to veto products intended to be marketed by the Gillette group; and6.benefited financially from sales both through direct profits and royalties payable under the know-how and licence agreement. The majority of the Court in that case found that although there were strong arguments both ways, the factors established a “good arguable case” for common design, sufficient to grant leave to join the overseas parent company to the proceedings. However, as in the comparison with Apotex (No 4) above, there are differences between the present circumstances and those that existed in Unilever v Gillette.